Expression of multidrug resistance gene in human cancers

Lori J. Goldstein, Hanan Galski, Antonio Fojo, Mark Willingham, Shinn Lian Lai, Adi Gazdar, Robert Pirker, Alexander Green, William Crist, Garrett M. Brodeur, Michael Lieber, Jeffrey Cossman, Michael M. Gottesman, Ira Pastan

Research output: Contribution to journalArticle

1164 Citations (Scopus)

Abstract

Many cancers have been cured by chemotherapeutic agents. However, other cancers are intrinsically drug resistant, and some acquire resistance following chemotherapy. Cloning of the cDNA for the human MDR1 gene (also known as PGY1), which encodes the multidmg efflux protein P-glycoprotein, has made it possible to measure levels of MDR1 RNA in human cancers. We report the levels of MDR1 RNA in >400 human cancers. MDR1 RNA levels were usually elevated in untreated, intrinsically drug-resistant tumors, including those derived from the colon, kidney, adrenal gland, liver, and pancreas, as well as in carcinoid tumors, chronic myelogenous leukemia in blast crisis, and cell lines of non-small cell carcinoma of the lung (NSCLC) with neu-roendocrine properties. MDR1 RNA levels were occasionally elevated in other untreated cancers, including neu-roblastoma, acute lymphocytic leukemia (ALL) in adults, acute nonlymphocytic leukemia (ANLL) in adults, and indolent non-Hodgkin's lymphoma. MDR1 RNA levels were also increased in some cancers at relapse after chemotherapy, including ALL, ANLL, breast cancer, neuroblastoma, pheochromocytoma, and nodular, poorly differentiated lymphoma. Many types of drug-sensitive and drug-resistant tumors, including NSCLC and melanoma, contained un-detectable or low levels of MDR1 RNA. The consistent association of MDR1 expression with several intrinsically resistant cancers and the increased expression of the MDR1 gene in certain cancers with acquired drug resistance indicate that the MDR1 gene contributes to multidrug resistance in many human cancers. Thus, evaluation of MDR1 gene expression may prove to be a valuable tool in the identification of individuals whose cancers are resistant to specific agents. The information may be useful in designing or altering chemotherapeutic protocols in these patients. [J Natl Cancer Inst 1989;81:116-124].

Original languageEnglish (US)
Pages (from-to)116-124
Number of pages9
JournalJournal of the National Cancer Institute
Volume81
Issue number2
DOIs
StatePublished - Jan 18 1989

Fingerprint

MDR Genes
RNA
Cancer
Genes
Gene
Leukemia
Tumors
Neoplasms
Chemotherapy
Acute
Drugs
Cells
Tumor
Glycoproteins
Cloning
Lung
Gene expression
Liver
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cell

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging
  • Oncology
  • Cancer Research

Cite this

Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S. L., Gazdar, A., ... Pastan, I. (1989). Expression of multidrug resistance gene in human cancers. Journal of the National Cancer Institute, 81(2), 116-124. https://doi.org/10.1093/jnci/81.2.116

Expression of multidrug resistance gene in human cancers. / Goldstein, Lori J.; Galski, Hanan; Fojo, Antonio; Willingham, Mark; Lai, Shinn Lian; Gazdar, Adi; Pirker, Robert; Green, Alexander; Crist, William; Brodeur, Garrett M.; Lieber, Michael; Cossman, Jeffrey; Gottesman, Michael M.; Pastan, Ira.

In: Journal of the National Cancer Institute, Vol. 81, No. 2, 18.01.1989, p. 116-124.

Research output: Contribution to journalArticle

Goldstein, LJ, Galski, H, Fojo, A, Willingham, M, Lai, SL, Gazdar, A, Pirker, R, Green, A, Crist, W, Brodeur, GM, Lieber, M, Cossman, J, Gottesman, MM & Pastan, I 1989, 'Expression of multidrug resistance gene in human cancers', Journal of the National Cancer Institute, vol. 81, no. 2, pp. 116-124. https://doi.org/10.1093/jnci/81.2.116
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A et al. Expression of multidrug resistance gene in human cancers. Journal of the National Cancer Institute. 1989 Jan 18;81(2):116-124. https://doi.org/10.1093/jnci/81.2.116
Goldstein, Lori J. ; Galski, Hanan ; Fojo, Antonio ; Willingham, Mark ; Lai, Shinn Lian ; Gazdar, Adi ; Pirker, Robert ; Green, Alexander ; Crist, William ; Brodeur, Garrett M. ; Lieber, Michael ; Cossman, Jeffrey ; Gottesman, Michael M. ; Pastan, Ira. / Expression of multidrug resistance gene in human cancers. In: Journal of the National Cancer Institute. 1989 ; Vol. 81, No. 2. pp. 116-124.
@article{f1b6b6680bfb4c558ba9f33bed21f2ce,
title = "Expression of multidrug resistance gene in human cancers",
abstract = "Many cancers have been cured by chemotherapeutic agents. However, other cancers are intrinsically drug resistant, and some acquire resistance following chemotherapy. Cloning of the cDNA for the human MDR1 gene (also known as PGY1), which encodes the multidmg efflux protein P-glycoprotein, has made it possible to measure levels of MDR1 RNA in human cancers. We report the levels of MDR1 RNA in >400 human cancers. MDR1 RNA levels were usually elevated in untreated, intrinsically drug-resistant tumors, including those derived from the colon, kidney, adrenal gland, liver, and pancreas, as well as in carcinoid tumors, chronic myelogenous leukemia in blast crisis, and cell lines of non-small cell carcinoma of the lung (NSCLC) with neu-roendocrine properties. MDR1 RNA levels were occasionally elevated in other untreated cancers, including neu-roblastoma, acute lymphocytic leukemia (ALL) in adults, acute nonlymphocytic leukemia (ANLL) in adults, and indolent non-Hodgkin's lymphoma. MDR1 RNA levels were also increased in some cancers at relapse after chemotherapy, including ALL, ANLL, breast cancer, neuroblastoma, pheochromocytoma, and nodular, poorly differentiated lymphoma. Many types of drug-sensitive and drug-resistant tumors, including NSCLC and melanoma, contained un-detectable or low levels of MDR1 RNA. The consistent association of MDR1 expression with several intrinsically resistant cancers and the increased expression of the MDR1 gene in certain cancers with acquired drug resistance indicate that the MDR1 gene contributes to multidrug resistance in many human cancers. Thus, evaluation of MDR1 gene expression may prove to be a valuable tool in the identification of individuals whose cancers are resistant to specific agents. The information may be useful in designing or altering chemotherapeutic protocols in these patients. [J Natl Cancer Inst 1989;81:116-124].",
author = "Goldstein, {Lori J.} and Hanan Galski and Antonio Fojo and Mark Willingham and Lai, {Shinn Lian} and Adi Gazdar and Robert Pirker and Alexander Green and William Crist and Brodeur, {Garrett M.} and Michael Lieber and Jeffrey Cossman and Gottesman, {Michael M.} and Ira Pastan",
year = "1989",
month = "1",
day = "18",
doi = "10.1093/jnci/81.2.116",
language = "English (US)",
volume = "81",
pages = "116--124",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Expression of multidrug resistance gene in human cancers

AU - Goldstein, Lori J.

AU - Galski, Hanan

AU - Fojo, Antonio

AU - Willingham, Mark

AU - Lai, Shinn Lian

AU - Gazdar, Adi

AU - Pirker, Robert

AU - Green, Alexander

AU - Crist, William

AU - Brodeur, Garrett M.

AU - Lieber, Michael

AU - Cossman, Jeffrey

AU - Gottesman, Michael M.

AU - Pastan, Ira

PY - 1989/1/18

Y1 - 1989/1/18

N2 - Many cancers have been cured by chemotherapeutic agents. However, other cancers are intrinsically drug resistant, and some acquire resistance following chemotherapy. Cloning of the cDNA for the human MDR1 gene (also known as PGY1), which encodes the multidmg efflux protein P-glycoprotein, has made it possible to measure levels of MDR1 RNA in human cancers. We report the levels of MDR1 RNA in >400 human cancers. MDR1 RNA levels were usually elevated in untreated, intrinsically drug-resistant tumors, including those derived from the colon, kidney, adrenal gland, liver, and pancreas, as well as in carcinoid tumors, chronic myelogenous leukemia in blast crisis, and cell lines of non-small cell carcinoma of the lung (NSCLC) with neu-roendocrine properties. MDR1 RNA levels were occasionally elevated in other untreated cancers, including neu-roblastoma, acute lymphocytic leukemia (ALL) in adults, acute nonlymphocytic leukemia (ANLL) in adults, and indolent non-Hodgkin's lymphoma. MDR1 RNA levels were also increased in some cancers at relapse after chemotherapy, including ALL, ANLL, breast cancer, neuroblastoma, pheochromocytoma, and nodular, poorly differentiated lymphoma. Many types of drug-sensitive and drug-resistant tumors, including NSCLC and melanoma, contained un-detectable or low levels of MDR1 RNA. The consistent association of MDR1 expression with several intrinsically resistant cancers and the increased expression of the MDR1 gene in certain cancers with acquired drug resistance indicate that the MDR1 gene contributes to multidrug resistance in many human cancers. Thus, evaluation of MDR1 gene expression may prove to be a valuable tool in the identification of individuals whose cancers are resistant to specific agents. The information may be useful in designing or altering chemotherapeutic protocols in these patients. [J Natl Cancer Inst 1989;81:116-124].

AB - Many cancers have been cured by chemotherapeutic agents. However, other cancers are intrinsically drug resistant, and some acquire resistance following chemotherapy. Cloning of the cDNA for the human MDR1 gene (also known as PGY1), which encodes the multidmg efflux protein P-glycoprotein, has made it possible to measure levels of MDR1 RNA in human cancers. We report the levels of MDR1 RNA in >400 human cancers. MDR1 RNA levels were usually elevated in untreated, intrinsically drug-resistant tumors, including those derived from the colon, kidney, adrenal gland, liver, and pancreas, as well as in carcinoid tumors, chronic myelogenous leukemia in blast crisis, and cell lines of non-small cell carcinoma of the lung (NSCLC) with neu-roendocrine properties. MDR1 RNA levels were occasionally elevated in other untreated cancers, including neu-roblastoma, acute lymphocytic leukemia (ALL) in adults, acute nonlymphocytic leukemia (ANLL) in adults, and indolent non-Hodgkin's lymphoma. MDR1 RNA levels were also increased in some cancers at relapse after chemotherapy, including ALL, ANLL, breast cancer, neuroblastoma, pheochromocytoma, and nodular, poorly differentiated lymphoma. Many types of drug-sensitive and drug-resistant tumors, including NSCLC and melanoma, contained un-detectable or low levels of MDR1 RNA. The consistent association of MDR1 expression with several intrinsically resistant cancers and the increased expression of the MDR1 gene in certain cancers with acquired drug resistance indicate that the MDR1 gene contributes to multidrug resistance in many human cancers. Thus, evaluation of MDR1 gene expression may prove to be a valuable tool in the identification of individuals whose cancers are resistant to specific agents. The information may be useful in designing or altering chemotherapeutic protocols in these patients. [J Natl Cancer Inst 1989;81:116-124].

UR - http://www.scopus.com/inward/record.url?scp=0024548599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024548599&partnerID=8YFLogxK

U2 - 10.1093/jnci/81.2.116

DO - 10.1093/jnci/81.2.116

M3 - Article

C2 - 2562856

AN - SCOPUS:0024548599

VL - 81

SP - 116

EP - 124

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -